Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute.
Cerament G product is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. Read more
Fractyl Laboratories today touted the publication of 1st-in-human data from a trial of its Revita duodenal mucosal resurfacing device and said it picked up former GI Dynamics medical chief Dr. David Maggs, who was fired last June, as its new chief medical officer.
Results from the study were published in Diabetes Care this month, Fractyl said. Read more
A Dutch supplier’s recall led to another headache for Cook Medical, already scrambling to recover from a massive catheter recall, when it prompted a partial recall of a wire guide used during peripheral vascular interventions.
The Bloomington, Ind.-based medical device giant said the supplier for the hydrophilic coating used on its Roadrunner Uniglide wire guides, Holland’s DSM Biomedical, recalled some product on concerns that it had been contaminated with glass particles ranging in size from 4µm to 280µm. Read more
Derma Sciences said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs.
Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs pegged to net sales growth. The deal, announced July 28, closed August 5, the company said in a regulatory filing. Read more
New details on the new health wearable Apple is said to be developing emerged yesterday when the U.S. Patent & Trademark Office released a patent application for a wrist- or ankle-worn device with electrocardiology features.
That fits in with rumors that surfaced earlier this week of Apple’s plan to develop a stand-alone device to monitor heart rate, pulse, blood and sugar changes. CEO Tim Cook has said that the healthcare market’s potential could dwarf the smartphone market that accounts for some 65% of Apple’s $234 billion in annual revenues. Read more